Drug Trial Radar · NCT05846230
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
268
Actual
Start
Sep 8, 2023
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term. Participants take a low, medium, or high dose of BI 1291583 as a tablet once a day for up to 1 year. Participants who were taking placebo in the AirleafTM or ClairaflyTM study are put into the BI 1291583 dosage groups randomly, which means by chance. Placebo tablets look like BI1291583 but do not contain any medicine. Participants who were taking BI 1291583 in the AirleafTM or ClairaflyTM study continue to take the same dose. Participants visit the study site 10 times and get 4 phone calls from the site staff. During the visits, the doctors collect information on any health problems of the participants. The doctors also check whether BI 1291583 helps reduce the symptoms of bronchiectasis.
Conditions
- Bronchiectasis
Interventions
BI 1291583Drug
Tablet
Placebo matching BI 1291583Drug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of treatment-emergent adverse events (TEAEs)Time frame: up to 12 months
Locations
103 sites in 22 countries. Site status is shown where the registry gives one.
Newport Native MD, Inc
Newport Beach, California
University of California Davis
Sacramento, California
Malcom Randall VA Medical Center
Gainesville, Florida
University of Florida Health Jacksonville
Jacksonville, Florida
University of Kansas Medical Center
Kansas City, Kansas
New York University Langone Medical Center
New York, New York
University of Cincinnati
Cincinnati, Ohio
Medical University of South Carolina
Charleston, South Carolina
Metroplex Pulmonary & Sleep Center
McKinney, Texas
IMA Clinical Research San Antonio
San Antonio, Texas
University of Texas Health Science Center at Tyler
Tyler, Texas
Macquarie University
Macquarie Park, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Lung Research Queensland
Chermside, Queensland, Australia
Mater Research Institute
South Brisbane, Queensland, Australia
Institute for Respiratory Health
Nedlands, Western Australia, Australia
Trialswest
Spearwood, Western Australia, Australia
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Medical Center Zdrave-1 OOD
Kozloduy, Bulgaria
Medical Center Hera - Montana Branch
Montana, Bulgaria
Medical Center ReSpiro Ltd
Razgrad, Bulgaria
Specialized Hospital For Active Treatment Of Pneumo-Phthisiatric Diseases Dr. Dimitar Gramatikov-Ruse
Rousse, Bulgaria
Medical Center Hera EOOD
Sofia, Bulgaria
Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ)
Québec, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada
Pulmonary Private Practice Kralupy
Kralupy nad Vltavou, Czechia
The First Pulmonary Private Practice
Prague, Czechia
Aalborg Sygehus Syd
Aalborg, Denmark
Hvidovre Hospital
Hvidovre, Denmark
Copenhagen University Hospital, Rigshospitalet
København Ø, Denmark
Odense University Hospital
Odense, Denmark
Sjællands Universitetshospital
Roskilde, Denmark
Vejle University Hospital
Vejle, Denmark
CHU Amiens-Picardie
Amiens, France
HOP Arnaud de Villeneuve
Montpellier, France
HOP Pontchaillou
Rennes, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
Essen, Germany
IKF Pneumologie GmbH & Co. KG
Frankfurt, Germany
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.